{
  "pmcid": "10077024",
  "sha256": "08ae05bc5f346a3224facd2cf8dfbf3720ecc93f8e6c7cc612f8a530a0ae9dd6",
  "timestamp_utc": "2025-11-09T21:51:21.666151+00:00",
  "model_used": "gpt-4o",
  "readability": {
    "flesch_kincaid": 12.818617154811715,
    "reading_ease": 24.443825313807565,
    "word_count": 239
  },
  "consort_scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "Randomised Controlled Trial of Polyethylene Glycol-Coated Haemostatic Patch in Reducing Clinically Relevant Postoperative Pancreatic Fistula"
      },
      "Trial_Design": {
        "score": 2,
        "evidence": "single-centre, open-label, parallel, two-arm, superiority randomised controlled trial"
      },
      "Participants": {
        "score": 2,
        "evidence": "Eligible participants were patients aged 18-80 years undergoing PD with pancreatojejunostomy for benign or malignant periampullary tumours."
      },
      "Intervention": {
        "score": 2,
        "evidence": "randomised 1:1 to receive pancreatojejunostomy reinforced with two polyethylene glycol-coated haemostatic patches (patch group) or without reinforcement (control group)."
      },
      "Objective": {
        "score": 1,
        "evidence": "This trial evaluated the impact of a polyethylene glycol-coated haemostatic patch on the incidence of clinically relevant postoperative pancreatic fistula (CR-POPF) after pancreatoduodenectomy (PD)."
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary outcome was CR-POPF within 90 days, defined as grade B/C according to International Study Group of Pancreatic Surgery criteria."
      },
      "Randomisation_Allocation": {
        "score": 2,
        "evidence": "Randomisation was performed using a secure internet-based service with allocation concealment."
      },
      "Blinding": {
        "score": 1,
        "evidence": "Data analysis was masked."
      },
      "Number_Randomised": {
        "score": 2,
        "evidence": "From 15 May 2018 to 22 June 2020, 72 patients were randomised"
      },
      "Number_Analysed": {
        "score": 2,
        "evidence": "72 patients were randomised, and 64 were analysed (31 in the patch group and 33 in the control group)."
      },
      "Result_Outcome": {
        "score": 3,
        "evidence": "The risk of CR-POPF was reduced by 90% (OR 0.10, 95% CI 0.01 to 0.89, P = 0.039)."
      },
      "Harms": {
        "score": 1,
        "evidence": "One patient died in the patch group versus three in the control group."
      },
      "Trial_Registration": {
        "score": 1,
        "evidence": "NCT03419676."
      },
      "Funding": {
        "score": 0,
        "evidence": "Funding: Not specified."
      }
    },
    "total_score": 22,
    "max_score": 25
  }
}